Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piperacillin-tazobactam/meropenem vs colistin/meropenem for ventilator-associated pneumonia due to carbapenem-resistant Klebsiella pneumoniae
IRCT20240229061132N1Phase 3Recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Dec 2024
- Modality
- Small Molecules, Peptides, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ventilator-associated pneumonia caused by carbapenem-resistant Klebsiella pneumoniae (CRKP-VAP) comparing piperacillin-tazobactam + meropenem with colistin + meropenem (2 arms). Primary endpoints: Clinical recovery rate and Mortality rate. Started Dec 2024; status: recruiting.
02
Drugs
piperacillin + tazobactammeropenemcolistin
03
Conditions
ventilator-associated pneumonia caused by carbapenem-resistant Klebsiella pneumoniae (CRKP-VAP)
Beyond the preview
Go deeper on IRCT20240229061132N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240229061132N1.